Entasis Therapeutics

Entasis Therapeutics, a subsidiary of Innoviva, Inc., is developing a portfolio of innovative cures for serious drug-resistant bacterial infections.

[Entasis Therapeutics @Entasistx]

We are proud to be part of biopharma Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., delivering innovative #CriticalCare and #InfectiousDisease therapies to patients.

Follow us @innovivastx moving forward. #ISTX #MedNews

https://t.co/8ScvfC3OMh

[Entasis Therapeutics @Entasistx]

We’re pleased to announce that an FDA Advisory Committee voted in support of approval of our investigational therapy for the treatment of adults with serious infections caused by susceptible strains of Acinetobacter.
https://t.co/E5AH4TYYXz

[Entasis Therapeutics @Entasistx]

Today we announced FDA acceptance for priority review of our NDA for SUL-DUR, a targeted antibiotic designed to treat CRAB and MDR Acinetobacter infections, a major public health concern associated with increased morbidity and mortality. $INVA
https://t.co/aYx6XEWOVN

[Entasis Therapeutics @Entasistx]

See what our chief medical officer, Dr. David Altarac, said about his time at #IDWeek2022

[Entasis Therapeutics @Entasistx]

Another great #IDWeek in the books! We are proud to have presented 6 posters this past week. Check them out here: https://t.co/ZTBwhrIxVz

[Entasis Therapeutics @Entasistx]

It’s great to be in-person at this year’s #IDWeek2022 and have the opportunity to meet and collaborate with colleagues both new and old. It’s inspiring to be surrounded by those committed to improving #PatientCare and #PublicHealth.

[Entasis Therapeutics @Entasistx]

Day 2 of #IDWeek2022 and we have two oral presentations today! Look out for our Chief Medical Officer, David Altarac and Chief Scientific Officer, Alita Miller as they present new data on SUL-DUR. Find us here: https://t.co/ck672KXa0C #IDWeek

[Entasis Therapeutics @Entasistx]

Today we announced the data that will be presented at this year’s #IDWeek. Learn more about how multiple sub-analyses provide additional validation of topline safety and efficacy data from Phase 3 ATTACK Trial: https://t.co/bAENeK6ZBm $ETTX

[Entasis Therapeutics @Entasistx]

Today we announced that we will share six presentations @IDWeek2022. We look forward to presenting our data on sulbactam-durlobactam (SUL-DUR) and connecting with others in the #InfectiousDisease space. View the full press release for more info: https://t.co/zv5Nq4eG68 #IDWeek

[Entasis Therapeutics @Entasistx]

Today we announced that we will be presenting data on our lead candidate, SUL-DUR, and ETX-0462 at the 2022 @ASMicrobiology Microbe Annual Conference. Read more about our presentations here: https://t.co/2TXbSknaFd $ETTX

[Entasis Therapeutics @Entasistx]

That’s a wrap on #ATS2022. Thank you to those who came to see our poster and presentation of #ClinicalData from our #Phase3 clinical trial. See the key takeaways here: https://t.co/gBx2c4XtZU @atscommunity

[Entasis Therapeutics @Entasistx]

Attending #ATS2022? We will be presenting #clinicalData from our global #Phase3 trial. See the data on our lead program on May 16th at 11:15 a.m. PT. Learn more about our presentation here: https://t.co/J8XBIH7TwZ @atscommunity

[Entasis Therapeutics @Entasistx]

Entasis CSO Ruben Tommasi, Ph.D., is featured in an article on @CARB_X discussing Entasis’ journey and the science behind developing novel treatments for #MultiDrugResistant pathogens. Read the full article here: https://t.co/YE7MTR56kM

[Entasis Therapeutics @Entasistx]

Today we announced our #FirstQuarter 2022 financial results and provided a business update. Learn more here: https://t.co/BjPnUNe2Yf $ETTX

[Entasis Therapeutics @Entasistx]

Today we shared safety and efficacy data from our Phase 3 ATTACK study that we presented at @ECCMID 2022. The full presentations are available on our website. More here: https://t.co/zYbE5wqqhG #ECCMID

[Patricia Bradford @P_A_Bradford]

Great thread here summarizing the results of the ATTACK trial run by @Entasistx for sulbactam-durlobactam against Acinetobacter. Really promising for this problematic organism

[Entasis Therapeutics @Entasistx]

Today we announced that we will share multiple presentations at @ECCMID 2022. We look forward to presenting our data and connecting with others in the #InfectiousDisease space. View the full release for more info: https://t.co/GPvOQcXgs3 #ECCMID

[Entasis Therapeutics @Entasistx]

Worldwide, there are 87 million new gonorrhea infections each year. This STD Awareness Week, @gardp_amr is highlighting our oral antibiotic #zoliflodacin being developed for the treatment of uncomplicated gonorrhea: https://t.co/CRPKPhm2dh #STDWeek

[Entasis Therapeutics @Entasistx]

Our CEO, Manos Perros, Ph.D., was featured in a recent @biospace article discussing the evolution of #AntimicrobialResistance and Entasis’ mission to develop precision medicines for patients with multi-drug resistant bacterial infections. Read more here: https://t.co/irMf0vJS7C

[Entasis Therapeutics @Entasistx]

New data from the #GRAMPaper estimates that there were 4.95M deaths in 2019 associated with AMR. The Entasis team is motivated to bring new treatment options to combat #MultidrugResistant pathogens. Read more here: https://t.co/9tvmmEVxom #ETTX #AMRSOS